Chronic pulmonary toxicity of methotrexate and rheumatoid arthritis
نویسندگان
چکیده
منابع مشابه
Liver Toxicity in Rheumatoid Arthritis Patients Treated With Methotrexate
Background:Methotrexate (MTX) is one of the most commonly used disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis (RA) which can be associated with toxic effects on different organs. This study was designed to investigate the hepatotoxic effects in RA patients treated with MTX. Methods: In this cross-sectional observational study, RA patients who received standard d...
متن کاملMethotrexate in rheumatoid arthritis: toxicity issues.
IT has been lOyr since the initial randomized placebo-controlled trials were published which established the short-term efficacy of low-dose weekly methotrexate in rheumatoid arthritis [1,2]. For the past 10 yr there has been an extensive clinical research programme including comparative studies of methotrexate versus auranofin [3], azathioprine [4], i.m. gold [5] and cyclosporin A [6], and lon...
متن کاملMethotrexate-related pulmonary complications in rheumatoid arthritis.
Methotrexate (MTX) was described as a drug in 1946' and first used in the treatment of human disease (childhood leukaemia) in 1948.2 Successful MTX treatment for rheumatoid arthritis (RA) and psoriasis was reported in 1951,3 although the interest in this drug at that time was probably overshadowed by the impressive results of cortico-steroid treatment until approximately 1980. MTX was approved ...
متن کاملliver toxicity in rheumatoid arthritis patients treated with methotrexate
background:methotrexate (mtx) is one of the most commonly used disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis (ra) which can be associated with toxic effects on different organs. this study was designed to investigate the hepatotoxic effects in ra patients treated with mtx. methods: in this cross-sectional observational study, ra patients who received standard do...
متن کاملMethotrexate in rheumatoid arthritis.
A variety of disease-modifying antirheumatic drugs (DMARDs) are available to control the clinical activity of rheumatoid arthritis (RA). Methotrexate (MTX), an analogue of folic acid and of aminopterin, is the most commonly used DMARD and is now prescribed worldwide to at least 500,000 patients with RA. The mechanism by which MTX used at a low dose modulates inflammation in RA is still unknown....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2003
ISSN: 1460-2172
DOI: 10.1093/rheumatology/keg188